-+ 0.00%
-+ 0.00%
-+ 0.00%
Liminatus Pharma Entered Definitive Agreement To Acquire InnocsAI On May 17 In $320M All-Stock Transaction
Share
Listen to the news

The proposed merger has been approved by the boards of directors/managers of both companies and remains subject to customary closing conditions, including shareholder approval, regulatory approvals and other conditions set forth in the Merger Agreement.

Additional information regarding the transaction will be included in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending